Cannabis Law Report

JANUARY 6, 2022

An especially worrisome development is the efforts of pharmaceutical companies to patent psilocybin products. This blog post will explain how psilocybin patenting and other factors could make Oregon’s psilocybin program prohibitively expensive for low-income patients, and how big pharma is maneuvering to monopolize psychedelic therapy.

Access 52

Access Patients Research and Development Treatment 52

Kind Meds (Cannabis Education Blog)

JUNE 27, 2021

At the same time, the pharmaceutical industry has become one of the most powerful businesses in the country. Big Pharma, which includes ten of the largest powers of the pharmaceutical industry, like businesses such as Johnson & Johnson, are heavily influential when it comes to political decisions in the U.S. Nerve pain.

Pharmaceutical 99

Pharmaceutical Chronic Pain Medicine Nerve Pain 99

MMJ Recs

AUGUST 1, 2024

While antiretroviral therapy (ART) has transformed HIV/AIDS from a fatal diagnosis to a manageable chronic condition, patients often endure chronic pain, nausea, appetite loss, and psychological distress. Medical marijuana for HIV/AIDS offers a promising complementary treatment for patients.

Patients 52

Patients Chronic Pain Marijuana Sleep 52

Cannabis Law Report

AUGUST 10, 2021

GW was initially granted marketing authorisation for this medicine in the UK in September 2019 as an adjunctive therapy for seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome, in conjunction with clobazam, for patients two years of age and older.

Pharmaceutical 98

Pharmaceutical Treatment Epilepsy Research and Development 98

Veriheal

SEPTEMBER 7, 2022

’s medical cannabis program come on the heels of a previously enacted emergency amendment focused on senior citizens: The Medical Marijuana Patient Access Extension Emergency Amendment Act of 2022 allowed D.C. A Temporary Triumph for Medical Cannabis Patients. These changes to D.C.’s Following Aug.

Patients 98

Patients Programs Access Treatment 98

Cannabis Law Report

JUNE 28, 2021

Pharmaceutical and Medical Cannabis Leaders Zambon GmbH and Adven GmbH will Drive Medical Cannabis Supporting Treatments for Neurological Therapies. The aim of the agreement is to make medical cannabis treatments available to patients, with an initial focus on neurological therapies. The market for medical cannabis in Germany.

Access 105

Access Research and Development Pharmaceutical Therapy 105

Cannabis Law Report

DECEMBER 11, 2021

. 'A monumental shame' @AndyMcDonaldMP continuing to highlight how families continue to be passed from pillar to post as the Government fail to continue to tackle the necessary barriers to widen access to life-saving #medicalcannabis prescriptions. pic.twitter.com/hACy4b79yH. — End Our Pain (@End_Our_Pain) December 10, 2021.

Treatment 52

Treatment Access Patients Medicine 52

Cannabis Law Report

AUGUST 22, 2021

. “The Janus particle solution will allow for time-released and combined therapies to be administered to patients, targeting specific indications. is using cutting-edge delivery technologies to develop safe and effective psychedelic pharmaceutical medicines. ” About Psycheceutical, Inc. Psycheceutical, Inc.

Pharmaceutical 98

Pharmaceutical Medicine Research and Development Therapy 98

Veriheal

SEPTEMBER 16, 2020

Epidiolex is the sole cannabis-derived pharmaceutical that has been approved by the FDA – although it is worth noting that the organization has also approved three synthetic cannabis-related products. About 85% of these patients experience epilepsy as an effect of the condition, and more than half are unable to achieve seizure control.

Access 98

Access Epilepsy Treatment Conditions 98

MMJ Recs

MAY 15, 2022

This initial MMJ legislation only allowed patients suffering from intractable epilepsy to use cannabis oil. But in the years since 2017, lawmakers have steadily improved Virginia’s medical marijuana program and made it accessible to a wider range of people. Recently, Virginia legalization has changed in several ways.

Patients 52

Patients Marijuana Pharmaceutical Dispensary 52

Cannabis Law Report

JUNE 23, 2021

Valcon Medical A/S Announces Receipt of EU GMP Certification and Start of Commercial Production for Pharmaceutical-Grade Cannabis Concentrates, Intermediary Products, and Medical Formulations (PRNewsfoto/Valcon Medical A/S).

Pharmaceutical 86

Pharmaceutical Concentrates Extraction Medicine 86

SpeedWeed

APRIL 9, 2021

Although this survey is specifically focused on Texas’ medical marijuana program, it also supports other research showing that cannabis can serve as an effective replacement for pharmaceuticals. This law allows a limited number of patients to use CBD-based medicine with no more than 0.5 percent THC content. View original article.

Pharmaceutical 52

Pharmaceutical Chronic Pain Programs Patients 52

Cannabis Law Report

AUGUST 17, 2021

reduction in 28-day seizure frequency relative to baseline in tuberous sclerosis complex (TSC) patients (n=23). reduction was observed in focal seizures (n=19), the most common seizure type in TSC patients. Phase 3 planning for TrustTSC trial ongoing with first patient expected to be enrolled in Q4 2021. RADNOR, Pa.–(BUSINESS

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

JUNE 1, 2022

This acquisition will accelerate Khiron’s growth in Europe by controlling the complete value chain for its products and gaining direct access to German pharmacies. Pharmadrug GmbH has been active worldwide for almost 40 years as a manufacturer and wholesaler of medicinal products and active pharmaceutical ingredients.

Pharmaceutical 52

Pharmaceutical Medicine Extraction Cannabinoids 52

NORML

JULY 1, 2019

Three new laws intended to expand patient access to and the therapeutic value of Virginia’s medical cannabis program take effect July 1, 2019. “These bills help ensure that all patients are able to obtain and use the necessary therapeutic doses of their cannabis medicines regardless of location or physical ability.”

Law 253

Law Patients Access Oil 253

Veriheal

JUNE 29, 2021

In order to legally access other therapies including nature-based options such as psilocybin , you must gain access under a Right to Try law which requires you to have a terminal condition. The FDA refers to this program as the expanded access program on their website. A Push by Patients. Patients Are Not In This Alone.

Therapy 64

Therapy DEA Patients Clinical Trials 64

Cannabis Law Report

SEPTEMBER 24, 2019

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. What about other medical cannabis products? ” Source BBC: [link]. PDF Version.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

MMJ Recs

NOVEMBER 17, 2023

This article explores the profound impact of MMJ on Maryland communities, shedding light on the medical marijuana benefits experienced by patients and the positive effects it has had on the state’s communities. It has improved the quality of life for those dealing with chronic pain, nausea, seizures, and other medical conditions.

Chronic Pain 98

Chronic Pain Therapy Research and Development Treatment 98

CannaTech

SEPTEMBER 23, 2019

The acceptance of medical cannabis by clinicians, researchers and government bodies is fairly universal, and patients have benefited from widespread access to full-spectrum cannabis in flower and oil form. Israel’s approach to cannabis has contributed to reducing stigma and increasing access for patients around the world.

Patients 79

Patients Policy Clinical Trials Research and Development 79

Cannabis Law Report

JUNE 5, 2019

Press Release: Thailand Government Pharmaceutical Organization. The Pharmaceutical Organization, Department of Medical Affairs, signed a joint research on standard quality medical marijuana extracts for patients with chemo-allergic cancer, epilepsy, muscle contraction in patients with deteriorating nerve sheaths.

Pharmaceutical 40

Pharmaceutical Extraction Epilepsy Research and Development 40

The Cannigma

SEPTEMBER 21, 2021

There are cannabis users, patients, and just everyday fans who may be fans, but don’t make it a big part of their public persona. For these famous medical cannabis patients and supporters, it is something that can improve quality of life and which should be made readily available to anyone in need. 1) Patrick Stewart. It’s tricky.”.

Patients 96

Patients Research and Development Sleep Clinical Trials 96

Veriheal

JUNE 22, 2021

Sue Sisley was quoted telling media, “there are thousands of different cannabis varieties that all have unique chemical profiles and produce unique clinical effects, but we didn’t have access to that normal diversity.” Another company that will be cultivating cannabis for research is a pharmaceutical research company.

DEA 65

DEA Access Therapy Cannabinoids 65

Canna Care Docs

NOVEMBER 4, 2024

Doctor is carefully examining a patient’s knee, providing personalized care and support. With a long history, it’s no surprise that patients still use medical cannabis to manage pain holistically. Patients dealing with chronic pain from numerous conditions are finding relief in cannabis. Since 2727 B.C.

Chronic Pain 111

Chronic Pain Nerve Pain Treatment Cannabinoids 111

LifeCannMD

AUGUST 30, 2024

Among them, one Medical Marijuana doctor stands out, offering compassionate care and expert guidance to patients seeking alternative treatments. Florida’s legalization of medical marijuana in 2016 marked a significant shift in how patients manage chronic conditions.

Marijuana 52

Marijuana Chronic Pain Treatment Pharmaceutical 52

Cannabis Law Report

SEPTEMBER 22, 2022

The Federal Parliament legalised the use of medicinal cannabis products in Australia in February 2016, but access to treatment is still severely limited due to cost, with patients reporting average monthly costs in excess of $300 , or approximately $10 per day. List Medicinal Cannabis on the PBS.

Pharmaceutical 52

Pharmaceutical Media Medicine Treatment 52

Cannabis Law Report

DECEMBER 5, 2021

The Multidisciplinary Association for Psychedelic Studies (MAPS) and Vine Ventures have announced the creation of a novel, social impact Special Purpose Vehicle (SPV), called the Regenerative Financing Vine (RFV), that will infuse $70 million into patient access infrastructure and research for MDMA-assisted therapy for PTSD.

Therapy 52

Therapy Access Research and Development Clinical Trials 52

Cannabis Law Report

JANUARY 18, 2022

Texas Original Compassionate Cultivation assembled a focus group of veterans suffering from PTSD to evaluate symptom response, product preference and effects on supplemental pharmaceutical consumption. To learn whether you or a loved one qualifies for medical cannabis, visit www.texasoriginal.com/patients. Emma Chase.

Patients 52

Patients Tincture Pharmaceutical Cultivation 52

Cannabis Law Report

MAY 2, 2023

Australian cannabis company Cannatrek has launched a not-for-profit organisation dedicated to providing support and access to medicinal cannabis therapies for vulnerable groups. Medicinal cannabis is still quite expensive, […]

Therapy 52

Therapy Pharmaceutical Medicine Treatment 52

NORML

FEBRUARY 23, 2020

Legislation is pending, Senate Bill 165, to establish a medical marijuana access program for qualified patients with a physician’s recommendation to access medical marijuana from licensed retail outlets. Send a message to your lawmakers in support of medical marijuana access. AL resident? AZ resident? California.

Legislation 242

Legislation Patients Decriminalization Access 242

Veriheal

SEPTEMBER 27, 2021

The United Kingdom’s Multiple Sclerosis (MS) Society has taken a stand against restricted access to medical cannabis in the country. The society launched a campaign with the hashtag #ApprovedButDenied protesting the difficulty so many patients have faced attempting to obtain medical cannabis. ApprovedButDenied.

Treatment 98

Treatment Patients Access Research and Development 98

SpeedWeed

MARCH 13, 2021

Almost 25% of patients with Parkinson’s disease reported that they had used cannabis in the prior six months in a survey from the Parkinson’s Foundation. Parkinson’s disease patients typically use pharmaceutical medications to treat their condition with varying degrees of success. More Than 1,000 PD Patients Surveyed.

Patients 52

Patients Treatment Therapy Sleep 52

Cannabis Law Report

JANUARY 5, 2022

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Treatment 52

Cannabis Law Report

JULY 21, 2022

COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that it has appointed Kabir Nath as Chief Executive Officer, effective August 1, 2022. London, UK July 19, 2022.

Therapy 52

Therapy Research and Development Pharmaceutical Patients 52

The NM Political Report | Medical Cannabis Program

JUNE 14, 2022

The cannabis company and medical cannabis patients are being represented by Christopher Saucedo, who is also a New Mexico State University regent and served last year on the state’s redistricting committee. The case seems to be the first of its kind in the nation.

Patients 40

Patients Banking Cannabis Treatment 40

NORML

JANUARY 24, 2019

It seeks to redefine allowed dosage limitations and formulations, and expand patient access and reduce patient cost by adding nurse practitioners and physician assistants to the list of those authorized to issue written certifications to patients. Marijuana policy should be evidence based.

Policy 158

Policy Patients Education Legislation 158

Cannabis Law Report

NOVEMBER 16, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced today that it has received U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. “Our Work with U.S. Christy Curran.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66